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Smallpox and monkeypox pose severe threats to human health. Other orthopoxviruses are
comparably virulent in their natural hosts, including ectromelia, the cause of mousepox. Disease severity is linked to an array of immunomodulatory proteins including the B22 family,
which has homologs in all pathogenic orthopoxviruses but not attenuated vaccine strains.
We demonstrate that the ectromelia B22 member, C15, is necessary and sufficient for
selective inhibition of CD4+ but not CD8+ T cell activation by immunogenic peptide and
superantigen. Inhibition is achieved not by down-regulation of surface MHC- II or co-stimulatory protein surface expression but rather by interference with antigen presentation. The
appreciable outcome is interference with CD4+ T cell synapse formation as determined by
imaging studies and lipid raft disruption. Consequently, CD4+ T cell activating stimulus shifts
to uninfected antigen-presenting cells that have received antigen from infected cells. This
work provides insight into the immunomodulatory strategies of orthopoxviruses by elucidating a mechanism for specific targeting of CD4+ T cell activation, reflecting the importance of
this cell type in control of the virus.

Author summary
Orthopoxviruses pose considerable threats to their hosts by producing a battery of proteins that disable the immune system at many levels through mechanisms that remain
poorly understood. An essential part of most immune responses is the activation of CD4+
T cells by antigen-presenting cells through formation of a supramolecular structure
termed the immunological synapse. We show here that the C15 protein of ectromelia, the
cause of mousepox, inhibits CD4+ T cell activation through a novel immunoevasion
mechanism that results in disruption of synapse formation. As many poxviruses encode
C15 homologs, these studies could provide insights into the virulence of other family
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members including monkeypox and smallpox, both of great concern to human
populations.

Introduction
CD4+ T cells are a critical adaptive immune cell type with roles in B cell and CD8+ T cell help,
inflammatory cytokine secretion and, in some cases, direct cytolytic function. The critical initiating events for CD4+ T cell activation are Major Histocompatibility Complex class II
(MHCII) presentation of pathogen derived peptides (epitopes) in combination with co-stimulatory signals through CD28 [1]. As CD4+ T cells play important roles in clearing many viral
infections, several mechanisms by which viruses inhibit MHCII antigen processing and presentation have been described [2]. For example, most steps of the MHCII maturation process
are targeted, from inhibition of the master transcription factor CIITA [3–8] to interference
with complex formation and trafficking [9–11], as well as forced degradation of mature
MHCII molecules [12, 13]. In addition, Hepatitis C Virus inhibits the function of endosomal
proteases required for generating some MHCII binding peptides [14]. Furthermore, EpsteinBarr virus (EBV) utilizes a soluble factor to block MHCII engagement with the T cell receptor
via steric hindrance [15, 16]. Of note, though discrete mechanisms of inhibition have been
described, there are relatively few examples of CD4+ T cell inhibition in the literature compared to the many of viral inhibition of MHCI presentation to CD8+ T cells, perhaps reflecting
historical inattention to the role of CD4+ T cells in viral clearance.
Another possible explanation for the dearth of inquiries into viral targeting of CD4+ T cells
is the prevailing view of the requirements for MHCII processing of antigen. The classical view
of MHCII presentation begins with internalization of extracellular material by a professional
antigen-presenting cell (APC), followed by processing of antigen within the endocytic network
and peptide loading onto nascent MHCII molecules in the late endosomal compartment [1].
However, the presentation of endogenously produced antigen following infection of the APC
via non-canonical processing pathways has been described in many viral systems [17–24].
Indeed, we have recently reported that during influenza infection the majority of MHCII presentation derives from endogenously produced proteins by directly infected APCs [24].
Importantly, the efficacy of inhibitory mechanisms that target MHCII processing and presentation generally necessitate direct infection of the APC. This reinforces the importance of
direct presentation by the infected APC in host defense.
Many orthopoxviruses can cause severe disease in humans, most notably smallpox, one of
the deadliest diseases in human history and an ongoing bioterrorism threat [25, 26]. Furthermore, zoonotic orthopoxviruses have emerged as novel disease causing agents; monkeypox
(MPXV) is passed human-to-human and is evolving to target the human immune system
more effectively [27]. Camelpox, cowpox and buffalopox can also cause severe infections in
humans [27]. Even vaccinia (VACV), the gold standard smallpox vaccination, is itself a live
virus that can cause disease and secondary transmission with potentially severe clinical complications in contraindicated persons [28].
Orthopoxviruses are the largest of the mammalian DNA-based viruses, encoding approximately 200 open reading frames (ORFs). Orthopoxviruses have strong conservation of viral
replication proteins but contain more diversity in the regions of the genome implicated in virulence [29–31]. For example, virulence factors interfere with interferon signals, block cytokine
signaling and impede innate intracellular antiviral pathways [32–51]. Importantly, many of
these ORFs have not yet been ascribed a specific function. Thus, many interactions between
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orthopoxvirus proteins and host factors have not yet been investigated. To this end, we utilized
the orthopoxvirus ECTV, as it is the causative agent of mousepox and has evolved as a natural
mouse pathogen [52]. Importantly, ECTV displays a similar disease profile as smallpox or
MPXV [52, 53]. In addition, ECTV causes much greater pathology in the mouse than the
smallpox vaccine virus vaccinia (VACV), despite their high degree of homology (>93%),
highlighting the importance of analyzing virulence factors in a setting that provides their natural targets.
CD4+ T cells are critical for the clearance of ECTV, helping to produce a strong neutralizing
antibody response as well as displaying cytolytic function in directly killing infected cells [54,
55]. Therefore, a strategy to target CD4+ T cells would be consistent with the major investment
in immune evasion characteristic of all orthopoxviruses. Here, we demonstrate that C15, the
largest immune evasion protein by size in the ECTV arsenal, a member of the B22 family of
proteins, and a considerable virulence factor [56], is necessary and sufficient to inhibit CD4+
but not CD8+ T cell activation via interference with synapse formation.

Results
Direct endogenous MHCII presentation is inhibited by ECTV
As ECTV is considerably more pathogenic in mice than the vaccine virus VACV, we initially
asked whether T cells, either CD4+ or CD8+, would respond differently to ECTV infection compared to VACV infection. We isolated CD4+ and CD8+ T cells from the spleens of ECTVinfected mice and co-cultured with bone marrow derived dendritic cells (BMDCs) infected
with either ECTV or VACV. T cell activation was measured using an IFNγ ELISpot. While we
observed robust CD8+ T cell activation to BMDCs infected with either virus, CD4+ T cell activation occurred only in the VACV-infected condition with minimal response to ECTV-infected
BMDCs (Fig 1A). This result suggests selective targeting of CD4+ T cell activation by ECTV.
We have previously reported on robust CD4+ T cell responses following ECTV infection
[57–59]. In light of this, the observed inhibitory effect suggests that MHCII processing and
presentation of ECTV antigens relies on indirect presentation of antigen by an uninfected
APC rather than direct presentation. As we have previously shown that direct endogenous presentation is the major driver of MHCII presentation during influenza infection [24], we compared modes of MHCII antigen presentation during influenza and ECTV infection. We
isolated CD4+ T cells from the spleens of influenza or ECTV infected mice, co-cultured with
BMDCs presenting MHCII peptides derived from either direct presentation or indirect presentation and measured T cell activation using an IFNγ ELISpot (Fig 1B). The direct presentation condition utilized virus-infected BMDCs, while the indirect presentation condition
employed virally infected MHCII- fibroblasts that would require antigen to be transferred to
BMDCs to allow for CD4+ T cell activation. Neutralizing antibody was included to prevent the
spread of infectious virus to BMDCs, thereby blocking the possibility of direct presentation.
Replicating our previously published findings [24], we determined that for influenza virus,
direct presentation resulted in significantly more robust CD4+ T cell activation compared to
indirect presentation (Fig 1B). For ECTV, in contrast, indirect presentation resulted in much
stronger CD4+ T cell activation compared to direct presentation (Fig 1B). Thus, ECTV-mediated inhibition of CD4+ T cell activation can be bypassed via indirect presentation of antigen
transferred to uninfected APCs.

C15 is an ECTV virulence factor but does not impact viral replication
To identify the factor responsible for CD4+ T cell inhibition by ECTV, we turned to the B22
family of proteins, named for the B22 open reading frame (ORF) in smallpox. A B22 family
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Fig 1. ECTV blocks direct MHCII presentation to CD4+ T cells. A) ECTV specifically targets MHCII but not MHCI
presentation. ECTV-specific CD4+ and CD8+ T cells were co-incubated with BMDCs infected with either VACV or
WT ECTV and analyzed for IFNγ production by ELISpot. B) Bias of influenza to direct MHCII presentation in contrast
to ECTV. PR8 influenza-specific or ECTV-specific CD4+ T cells were co-incubated in the presence of neutralizing
antibody with either BMDCs infected with virus (direct presentation) or infected fibroblasts and uninfected BMDCs
(indirect presentation). CD4+ T cell activation was measured via IFNγ production by ELISpot. Each dot represents the
mean spot count of technical replicates of an independent infection of BMDCs or fibroblasts, with three infections per
condition. Representative of three-eight independent experiments. Significance analyzed by student’s T test, � p<0.05,
���
p<0.001, ���� p<0.0001, error bars signify (A) square root of squared SEMs or (B) SEM.
https://doi.org/10.1371/journal.ppat.1008685.g001

protein is present in all pathogenic orthopoxviruses, including ECTV, but is highly truncated
in VACV (~1% of the coding sequence remains) (Fig 2A). In addition, previous reporting on
the B22 family member of ECTV, C15, and B22 family members of other pathogenic poxviruses described general inhibition of T cell responses [56, 60]. To analyze whether the B22 protein encoded by ECTV, C15, played a role in the inhibitory phenotype observed above, we first
generated a virus via standard recombination methods [61] in which the majority of the C15
coding sequence was replaced with the GFP gene (ECTVΔC15). Subsequently, we created a
C15 revertant ECTV (ECTVrevC15) by homologous recombination.
To validate that C15 does not play a role in viral replication, we performed an in vitro
growth curve in fibroblasts comparing ECTVΔC15, ECTVrevC15, and w.t. ECTV engineered
to express GFP [62]. We observed that the loss of C15 has no effect on viral replication in vitro,
which is often the case for immunomodulatory gene products (Fig 2B). In addition, we analyzed the in vitro replication kinetics in BMDCs and observed no impact of C15 on viral replication (Fig 2C). To analyze the impact of C15 on virulence, we infected ECTV-susceptible
BALB/c mice with ECTVΔC15 or ECTVrevC15 and observed that C15 is a strong virulence
factor in vivo since all mice infected with ECTVΔC15 survived (Fig 2D). Interestingly, footpad
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Fig 2. C15 is a virulence factor that is not required for viral replication. A) Amino acid sequences for the B22 family
members in ECTV Moscow, VARV BG1975, CPXV Brighton Red or MPXV Zaire were analyzed for sequence
similarity via pBLAST (NCBI), with sequence differences highlighted. Sequences were obtained from the Viral
Bioinformatics Resource Centre. B-C) Either B) C57Bl/6 fibroblasts or C) BMDCs were infected with WT ECTV
(GFP), ECTVΔC15 or ECTVrevC15 at a MOI of 3 in triplicate and infectious lysates were harvested at various times
post infection and analyzed for infectious units via focus forming assay. Representative of two independent
experiments. Significance analyzed by two way ANOVA, error bars signify SEM. D) BALB/c mice were infected with
either ΔC15 ECTV or ECTVrevC15 and morbidity and mortality were assessed daily. Representative of two
independent experiments. Significance analyzed by Kaplan-Meier estimate, �� p<0.01.
https://doi.org/10.1371/journal.ppat.1008685.g002

inflammation leading to foot necrosis was still observed in the mice infected with ECTVΔC15
(S1 Fig). Together these data are in agreement with the previous report that C15 is a virulence
factor in vivo but is dispensable for viral replication [56].

C15 restricts CD4+ but not CD8+ T cell activation
Our data in Fig 1 suggest that ECTV specifically inhibits CD4+ T cell activation. However,
published work with other B22 family members demonstrated a role for inhibition of both
CD4+ and CD8+ T cells [60]. We therefore examined the role of C15 in blocking CD4+ and
CD8+ T cell activation by isolating T cells, either CD4+ or CD8+, from the spleens of ECTV
infected mice, co-culturing with BMDCs infected with either ECTVΔC15 or ECTVrevC15,
and analyzing T cell activation via IFNγ ELISpot (Fig 3A). We observed that CD8+ T cells
were robustly re-activated by the re-stimulating virus independent of C15 expression, but that
CD4+ T cell responses were significantly suppressed in the presence of C15 (Fig 3A). In addition, we analyzed the relative contributions of direct and indirect presentation in the presence
and absence of C15. In agreement with our hypothesis, we observed that C15 had no role in
inhibiting indirect presentation but rather specifically inhibited direct presentation (S2 Fig).
These data demonstrate that ECTV C15 is necessary to inhibit CD4+ but not CD8+ T cell
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Fig 3. C15 is necessary and sufficient for selective inhibition of CD4+ T cell activation. A) ECTV-specific CD4+ or
CD8+ T cells were co-incubated with BMDCs infected with ECTVΔC15 or ECTVrevC15 and analyzed for IFNγ
production by ELISpot. Representative of three-eight independent experiments. B-D) B6-IEd fibroblasts were
transfected with C15-HA prior to staining for surface expression of HA tag and sorting based on HA tag expression.
Cells were pulsed with B) HA-16 (I-Ab restricted), C) S3 (I-Ed restricted) or D) SIINFEKL (Kb restricted) peptide and
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then co-cultured overnight with T cell hybridomas specific for each peptide. T cell activation was measured by proxy of
β-galactosidase conversion of MUG substrate. Representative of three independent experiments. Significance analyzed
by student’s T test, � p<0.05, �� p<0.01, ��� p<0.001, error bars signify square root of squared SEMs.
https://doi.org/10.1371/journal.ppat.1008685.g003

activation. Moreover, C15 specifically targets direct presentation by MHCII, a fundamentally
different mechanism of action relative to the MPXV homolog of B22.

C15 is sufficient for selective inhibition of CD4+ T cell activation
In order to analyze the impact of C15 in isolation on T cell activation, we created a mammalian
expression vector encoding C15 with a C-terminal HA tag (C15-HA). As has been previously
shown for the VARV, MPXV, and CPXV homologs [60, 63] and predicted in silico [64], we
observed the C terminus to be extracellular via flow cytometric analysis of the HA tag (S3 Fig).
As transfection of BMDCs is technically challenging, we employed the C57Bl/6-CIITA-IEd
fibroblast cell line (B6-IEd), a tool we have used frequently to study MHCII presentation by
both IAb and IEd MHCII molecules [22, 24, 65]. We transfected B6-IEd cells with the C15-HA
construct and sorted the populations based on HA-tag expression. We then pulsed both populations with specific IAb or IEd- restricted influenza peptides and co-cultured APCs overnight
with a panel of T cell hybridomas, each specific for a given peptide. For CD4+ T cell hybridomas specific for an IAb- restricted epitope (Fig 3C) or an IEd-restricted epitope (Fig 3D), the
presence of C15 significantly impacted activation. In contrast, activation of a CD8+ T cell
hybridoma was not diminished by the presence of C15 (Fig 3E). These data show that C15 is
sufficient for selective inhibition of CD4+ T cell activation.

C15 inhibition is independent of MHCII or co-activation protein surface
downregulation
Many viral proteins that inhibit MHCII processing and presentation act via downregulation of
surface MHCII levels, either by blocking transcription or by degrading mature MHCII molecules [3–8, 12, 13]. To determine if C15 inhibits CD4+ T cell activation in this manner or by
targeting the classical co-activation proteins CD80 and CD86, we infected BMDCs with either
ECTVΔC15 or ECTVrevC15 overnight and analyzed surface levels of MHCII (Fig 4A and
4B), CD80 (Fig 4C and 4D) and CD86 (Fig 4E and 4F) via flow cytometry. We did not
observe any differences in either the percent of cells expressing these proteins (Fig 4A, 4C and
4E) or levels expressed at the cell surface (mean fluorescence intensity, MFI) (Fig 4B, 4D and
4F). Therefore, C15 does not inhibit CD4+ T cell activation by downregulating surface levels of
MHCII, CD80 or CD86.

C15 inhibition of MHCII presentation is mediated in cis
Since C15 does not function in a straightforward manner by downregulation of MHCII or costimulatory proteins, we analyzed whether C15-dependent effects on CD4+ T cell activation
require expression of C15 by the APC or if C15 can block CD4+ T cell activation in trans. We
transfected MHCII negative CHO cells with C15-HA, sorted cells based on HA expression,
and then co-cultured them with BMDCs pulsed with peptide and antigen-specific CD4+ T cell
hybridomas. We observed robust CD4+ T cell activation by BMDCs regardless of whether the
co-cultured CHO cells expressed C15 (Fig 5), indicating that C15 must be expressed in cis on
the APC in order to inhibit CD4+ T cell activation. This finding is consistent with our data in
Fig 3 that C15 specifically targets direct presentation by the infected APC.
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Fig 4. C15 does not inhibit surface expression of MHCII or co-activation proteins. BMDCs were infected
independently with either ECTVΔC15 or ECTVrevC15 overnight and stained for surface expression of A-B) MHCII,
C-D) CD80 or E-F) CD86. Flow cytometry data was analyzed for A,C,E) percent of cells expressing or B,D,F) mean
fluorescence intensity for each protein. Each dot represents an independent infection of BMDCs, with three infections
per condition. Representative of three independent experiments. Significance analyzed by student’s T test, error bars
signify SEM.
https://doi.org/10.1371/journal.ppat.1008685.g004

C15 does not function by inhibiting peptide loading
The previous experiments do not rule out the possibility that C15 functions by inhibiting peptide loading onto MHCII during MHCII maturation. To investigate this possibility, we analyzed whether C15 inhibition could block T cell activation by pre-loaded peptide-MHCII. We
generated a series of CHO recombinant cell lines that stably expressed an MHCII (IEd allele)
molecule containing a peptide covalently bound within the binding groove (S4 Fig). We transfected three independent cell lines (each presenting a different IEd-restricted influenza epitope) with C15-HA, sorted populations based on HA tag expression, and subsequently cocultured the sorted populations overnight with CD4+ T cell hybridomas recognizing each of
the three epitopes. We observed that all three MHCII-single chain epitope constructs were significantly less able to activate their cognate CD4+ T cell hybridoma in the presence of C15 (Fig
6A–6C). This indicates that C15-mediated inhibition operates independent of peptide loading.
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Fig 5. C15 inhibits MHCII presentation in cis. CHO cells were transfected with C15-HA for 24 hours. Cells were
stained for surface expression of HA, sorted based on HA expression and co-cultured with BMDCs pulsed with HA-16
peptide and an HA-16 specific T cell hybridoma. T cell activation was measured by proxy of β-galactosidase
conversion of MUG substrate. Representative of three independent experiments. Significance analyzed by student’s T
test, error bars signify square root of the squared SEMs.
https://doi.org/10.1371/journal.ppat.1008685.g005

C15 suppresses superantigen-mediated CD4+ T cell activation
In light of C15 functioning independent of peptide loading, we asked whether C15 could also
prevent superantigen- mediated T cell activation, which crosslinks MHCII and the TCR without a requirement for MHC-loaded peptide [66, 67]. We isolated splenic CD4+ T cells from
mice infected with PR8 influenza as a source of activated T cells for analysis of superantigenmediated stimulation. These were co-cultured with BMDCs infected with either ECTVΔC15
or ECTVrevC15 in the presence of Staphylococcal enterotoxin B (SEB) and analyzed for T cell
activation via IFNγ ELISpot. SEB stimulated significantly fewer CD4+ T cells in the presence of
C15 (Fig 7). The result solidifies the conclusion that the C15 mechanism of action does not
entail inhibition of peptide loading.

C15 specifically inhibits CD4+ T cell synapse formation
Thus far we have demonstrated that the mechanism of C15 inhibition does not involve downregulation of MHCII, CD80 or CD86, requires C15 to be on the same cell as the MHCII, and is
not attributable to interference with loading of peptide onto MHCII. In light of these findings,
as well as the localization of C15 at the plasma membrane (S3 Fig), we investigated whether
C15 expression results in blockage of CD4+ T cell immunological synapse formation. This line
of investigation was important for mechanistic insight since T cell activation can be inhibited
without disruption of the synapse [68]. Accordingly, we analyzed synapse formation via confocal microscopy in the presence and absence of C15. For these studies we utilized the B6-IEd
cells, which constitutively produce the Eα-IAb complex and can be tested for MHCI presentation by peptide pulsing with the Kb-restricted SIINFEKL peptide. In preliminary experiments,
we confirmed that these cells can promote T cell synapse formation by co-culturing B6-IEd
cells with T cells from TCR transgenic mice, either CD4+ T cells from naïve TEα (which recognize Eα-IAb) [69] (Fig 8A) or CD8+ T cells from naïve OT-I (which recognize SIINFEKL-Kb)
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Fig 6. C15 does not function by inhibition of peptide loading. A-C) CHO cells engineered to stably express I-Ed
covalently bound to peptide in the binding groove, either A) S1 B) S3, or C) NA-79 were transfected with C15-HA for
24 hours. Cells were stained for surface expression of HA and sorted based on HA expression. Cells were co-cultured
with T cell hybridomas specific for each peptide. T cell activation was measured by proxy of β-galactosidase conversion
of MUG substrate, with background signal from CHO parental cells cultured with T cell hybridomas subtracted from
sample wells. Representative of three independent experiments. Significance analyzed by student’s T test, �� p<0.01, ���
p<0.001, error bars signify square root of the squared SEMs.
https://doi.org/10.1371/journal.ppat.1008685.g006

[70] (Fig 8C). To analyze the impact of C15 on T cell synapse formation, we transfected
B6-IEd cells with either C15-HA or HA-tagged Guanyl Cyclase C- (GCC-HA), an unrelated
large membrane protein, and co-cultured these APCs with either CD4+ T cells from TEα mice
or CD8+ T cells from OT-I mice. We assessed T cell synapse formation by staining for F-actin,
as F-actin accumulation at the APC/T cell interface in the T cell is a well characterized event in
synapse formation [71] (Fig 8A and 8C). We counted the number of B6-IEd APCs, either +GCC-HA, +C15-HA or -C15-HA (from same well as +C15-HA), that formed unambiguous
synapses with T cells, either CD4+ (Fig 8B) or CD8+ (Fig 8D). We observed that CD4+ T cells
significantly less frequently formed a synapse with a +C15-HA B6-IEd cell. In contrast, CD8+
T cell synapse formation was unaffected by the presence of C15. Furthermore, transfection
with the unrelated GCC-HA membrane protein did not affect synapse formation of either
CD4+ or CD8+ T cells. From these data, we conclude that C15 expression prevents formation
of a functional CD4+ T cell synapse.

Discussion
Here we have demonstrated that the orthopoxvirus ECTV, the causative agent of mousepox,
targets direct MHCII processing and presentation to CD4+ T cells. Furthermore, we show that
the B22 family protein C15, a virulence factor not involved in virus replication, is necessary
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Fig 7. C15 prevents superantigen-mediated CD4+ T cell activation. PR8-specific CD4+ cells were co-incubated with
BMDCs infected with ECTVΔC15 or ECTVrevC15 in the presence of 2 ug/mL SEB and analyzed for IFNγ production
by ELISpot. Representative of three independent experiments. Significance analyzed by student’s T test, �� p<0.01,
error bars signify square root of the squared SEMs.
https://doi.org/10.1371/journal.ppat.1008685.g007

and sufficient to inhibit CD4+ but not CD8+ T cell activation. Importantly, C15-mediated inhibition is contingent upon expression by the APC, rather than a bystander cell. Furthermore,
we provide evidence that C15 does not function by downregulating surface MHCII or co-activation proteins or by blocking peptide loading. Rather, C15 functions post-peptide loading,
resulting in substantially diminished CD4+ T cell synapse formation, the crucial early step in
the CD4+ T cell activation program. The only other viral protein we are aware of that functions
independently of MHCII surface downregulation or peptide loading is gp42 of EBV, which
sterically hinders the interaction between human TCRs and MHCII [15, 16] by binding the β1
domain of MHCII, near the peptide binding groove [16]. Notably, this protein is soluble,
implying a trans effect and a fundamentally different mechanism. Furthermore, as EBV is a
persistent virus that specifically replicates in B cells and ECTV is an acute virus with broad cell
tropism, these viruses have likely evolved to inhibit CD4+ T cells for distinct purposes.
Both ECTV and C15 specifically have been previously implicated in interference with CD4+
T cell function, however without elucidation of underlying mechanism. ECTV has been suggested to interfere with dendritic cell activation, though the responsible viral factor was not
identified [72, 73]. A previous publication described C15 as a virulence factor that targets both
CD4+ and CD8+ T cells [56]. However, mechanism of action was not explored and outcomes
did not allow for distinction between direct inhibition of both T cell subsets and the possibility
of indirect effects on CD8+ T cells via CD4+ T cell repression. Here we directly examined the
effect of C15 on CD4+ and CD8+ T cell activation both in the context of viral infection and
expression of C15 in isolation. In a variety of experimental settings, with both hybridomas and
primary ex vivo cells, we did not observe inhibition of CD8+ T cells. While we measured only
IFNγ to assess primary CD8+ T cell activation, our observation that MHCI synapse formation
was unimpacted by C15 expression implies that we did not overlook inhibition of alternative
CD8+ T cell effector functions.
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Fig 8. C15 specifically inhibits CD4+ T cell synapse formation. B6-IEd fibroblasts pulsed with SIINFEKL peptide
were transfected with C15-HA or GCC-HA for 24 hours. Cells were co-cultured with A,B) CD4+ T cells from a naïve
TEα mouse (TCR transgenic against Eα-I-Ab) or C,D. CD8+ T cells from a naïve OT-I mouse (TCR transgenic against
SIINFEKL-Kb). Following co-culture, plates were gently washed, fixed, and stained with DAPI as well as antibodies
against actin, HA and CD3. A,C) Representative images of a A) CD4+ T cell or C) CD8+ T cell forming a synapse with
untransfected B6-IEd fibroblast. B,D) The percent of B6-IEd fibroblasts expressing GCC-HA or C15-HA or C15-HA
negative cells in proximity to C15-HA+ cells inducing B) CD4+ T cell or D) CD8+ T cell synapse formation. This data
is the pooled cell counts from at least two independent experiments per condition. Significance analyzed by Chi Square
test, ���� p<0.0001.
https://doi.org/10.1371/journal.ppat.1008685.g008

Several members of the B22 family have been implicated as critical poxviral virulence factors [56, 60, 74, 75] but interestingly, various lines of evidence suggest that different members
of the B22 family have distinct mechanisms of action despite relatively high conservation at
the sequence level. The Früh lab has demonstrated that the MPXV B22 family protein,
MPXV197, is capable of inhibiting both CD4+ and CD8+ T cells [60], in contrast to our work
with C15. Furthermore, C15 requires synthesis in an MHCII+ APC in order to inhibit T cell
activation, whereas MPXV197 can function in trans when present on a bystander non-APC.
These data suggest intriguing possibilities for structural differences between C15 and
MPXV197 that dictate the respective functions of the two proteins. For example, it is currently
unknown whether the N terminus of C15 is intracellular; the N-terminus of the MPXV homolog was demonstrated to be intracellular [60] while the orientation of the CPXV homolog
could not be resolved [63]. Greater understanding of the specific inhibitory mechanisms
employed will likely require more detailed structural information on the various B22 family
members.
That C15 localizes to the plasma membrane of the APC and hinders superantigen-mediated
CD4+ T cell activation offers intriguing mechanistic possibilities. As SEB is known to interact
with the α-chain of MHCII near but outside of the peptide binding groove [76], it is possible
that C15 sterically hinders the interaction of MHCII with the TCR or SEB without altering the
conformation of MHCII. Likewise, C15 might force structural alterations in MHCII that
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decrease affinity for TCR interaction. An intriguing alternative is that C15 interferes with
MHCII movement within the plasma membrane, possibly sequestering MHCII outside of activating lipid rafts, which are critical for both SEB-mediated T cell activation and productive
immunological synapse generation [77]. Ongoing studies are exploring these possibilities and
whether the mechanism requires direct interaction between C15 and MHCII. In addition, the
selective impact of C15 on CD4+ but not CD8+ T cell synapse formation could be a useful tool
for greater understanding of the mechanisms underlying activation of these two subsets.
Indeed, while the synapse structure is known to differ depending on cytolytic capacity of the T
cell [78–80], there are differences between CD4+ and CD8+ T cell synapses independent of this
property [81].
The critical first step in CD4+ T cell activation comes from engagement of the T cell receptor with a foreign peptide being presented in complex with MHCII molecules. Historically,
these peptides were thought to originate from material endocytosed by a professional APC for
subsequent degradation and loading onto immature MHCII molecules within the endocytic
network [1]. However, there is increasing evidence that endogenous MHCII antigen processing and presentation by a directly infected cell can drive CD4+ T cell activation [17–24] and, in
the case of influenza, accounts for the large majority of CD4+ T cell expansion [24]. Importantly, many viruses are able to infect professional APCs such as dendritic cells and most cells
can upregulate MHCII when stimulated with IFNγ [82, 83], suggesting that direct endogenous
MHCII processing is a common phenomenon during viral infection. If endogenous MHCII
presentation by infected cells is an important aspect of host defense, then pathogens can be
expected to develop strategies to overcome this system. Indeed, most of the reported viral
mechanisms for inhibition of MHCII processing and presentation depend on direct infection
of the APC, for example, repression of MHCII transcription and forced degradation of mature
MHCII molecules [2]. During ECTV infection it is known that infected MHCII+ cells facilitate
viral systemic spread [84, 85] and that a cytolytic CD4+ T cell response is elicited [54]. The
increased viral virulence in the presence of C15 suggests that direct presentation might also be
critical in identifying virally infected cells for targeting by cytolytic CD4+ T cells.
Previous studies from our lab have demonstrated robust epitope-specific CD4+ T cell activation during ECTV infection [57–59], suggesting that blockade of direct endogenous MHCII
presentation is bypassed in some way. While C15 inhibition is robust, it is not complete, and
this may provide a partial explanation. More intriguing is the possibility that indirect MHCII
presentation is a major driver of ECTV-specific CD4+ T cell responses in vivo. This would contrast with the minor role played by indirect presentation in influenza infections [24]. Our in
vitro results support this hypothesis and future in vivo studies will seek to test this directly.
Currently, little is known about the cellular machinery that supports indirect presentation and
the extent to which classical exogenous antigen processing is used for this purpose. Furthermore, it is possible that the necessity of relying on indirect processing for MHCII presentation
results in less robust CD4+ T cell responses due to decreased diversity of peptide display. That
ECTV appears to utilize indirect MHCII presentation, perhaps due to C15 evolutionary pressure, suggests that this system could be a useful model for greater understanding of alternative
MHCII presentation pathways.
In this work we demonstrate that ECTV employs a novel mechanism for evading CD4+ T
cell responses which results in inhibition of MHCII/TCR synapse formation. This adds to the
relatively limited list of pathogen-encoded inhibitory strategies that target CD4+ T cell activation [2]. While much of the literature to date has focused on viral inhibition of MHCI processing and presentation, with increased interest in CD4+ T cells and the elucidation of a more
complex MHCII processing and presentation landscape, it seems likely that many more
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instances of viral targeting of the MHCII processing and presentation system remain to be
identified.

Materials and methods
Ethics statement
Animal studies performed in this study fall under an animal protocol approved by the Children’s Hospital of Philadelphia Research Institute Institutional Animal Care and use Committee (protocol id 15–001314). The Children’s Hospital of Philadelphia is an AAALAC
accredited institution and adheres to the standards set by the Animal Welfare Act and the NIH
Guide for the Care and Use of Laboratory Animals.

Primary APCs and cell lines
Bone marrow dendritic cells (BMDCs) were derived from the bone marrow of pooled female
C57BL/6 mice (The Jackson Laboratory, 00064) and cultured for 7–10 days in RPMI 1640
(10% FBS, antibiotics, L-glutamine, and 2-ME) with GM-CSF (Gemini Bio-Products). B6-IEd
fibroblasts have been previously described [22, 24, 65] and were cultured in DMEM supplemented with 5% FBS, antibiotics and L-glutamine. L929 cells (ATCC CCL-1) were cultured in
DMEM supplemented with 5% FBS, antibiotics and L-glutamine. BSC-1 cells were cultured in
DMEM supplemented with 10% FBS, antibiotics and L-glutamine. T cell hybridomas previously described [21, 24, 86, 87] were maintained in RPMI supplemented with 10% FBS, 1×penicillin/streptomycin, 1×L-glutamine and 0.05 mM 2-ME. The epitope-linked MHCII stable
CHO cell lines, similar to previous reports [88], were generated via double transfection of
pCMV-IEd-α and pCMV-IEd-β-epitope plasmids. The epitopes (S1, S3, and NA79) were
linked to IEd-β via an N-terminal poly-4xGly-Ser linker. Transfection was accomplished with
Lipofectamine 2000 (ThermoFisher 11668) reagent in 24-well plates following the manufacturers recommended protocol. After 48 hours, the transfected cells were placed under Geneticin
(500ug/mL) selection for 5 days. After selection, IEd expression was verified by flow cytometry
(clone M5.114.15.2, Biolegend). Epitope expression was verified via MUG assay by co-incubating the CHO-IEd-epitope stable cell lines with T-cell hybridomas specific to S1, S3, and NA79
(S4F Fig). CHO-IEd-epitope cell lines were cultured in DMEM supplemented with 5% FBS,
antibiotics and L-glutamine.

Mouse models of infection
C57Bl/6 (JAX 000664) and BALB/c (JAX 000651) mice were purchased from Jackson Laboratories. C57Bl/6 mice were infected with either 3 x 103 pfu of ECTV or alternatives as described
below. Spleens from naïve TEα mice were a kind gift from the lab of Ivan Maillard (University
of Pennsylvania). Spleens from naïve OT-I mice were a kind gift from the Christopher Hunter
(University of Pennsylvania) and Edward Behrens labs (Children’s Hospital of Philadelphia
Research Institute). All mice utilized for this study were females ranging from 6–10 weeks in
age. All animals were age matched within an individual experiment.

Viruses and virus purification
The following poxviruses viruses were used during the course of this work: ECTV expressing
GFP (Moscow strain background; gift of Dr. Luis Sigal [62]), ECTVΔC15 (Moscow strain),
and ECTVrevC15. ECTVΔC15 was constructed using standard homologous recombination
techniques [56]. Approximately 75% of the C15 open reading frame was replaced with the coding sequence for GFP under the transcriptional control of the poxvirus p7.5 early/late
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promoter. After the infection/transfection stage, a GFP-positive plaque was isolated and subsequently underwent five rounds of passage in BS-C-1 cells to ensure that 100% of plaques stably
expressed GFP. As a control, we also constructed a revertant virus (ECTVrevC15) in which the
native open reading frame was recombined back into ECTVΔC15. For virus purification, TKcells were infected for 72 hours followed by lysis using repeated freeze, thaw, sonication cycles.
The cell lysate was then purified through a 36% sucrose cushion and resuspended in 1 mM
Tris-HCL for use in animal and in vitro experiments. Viral titers were obtained via plaque
assay on BSC-I cells. Influenza A virus, A/Puerto Rico/8/1934 (PR8), subtype H1N1 was
grown, harvested, titered, and plaqued from isolates as described previously [21, 24, 89]. One
hemagglutinating unit (HAU) of live PR8 virus �1.5 × 105 plaque-forming units, titered as
previously described [89].

C15-HA plasmid generation
A C15 ORF codon optimized for human cells was generated commercially (GenScript). Using
standard PCR and restriction enzyme-based cloning, the ORF was inserted into the commercially available CMV c-terminal- HA tag plasmid (Clontech 635690) via Sal1 and Kpn1 restriction enzyme sites. Ampicillin-resistant colonies were screened using restriction enzyme
digestion following plasmid isolation. Insert expression was verified by a Western blot against
the HA tag after transfection into 293T cells.

ELISpot assay
Female C57BL/6 mice 6–8 weeks of age were inoculated with appropriate virus (three mice per
group). ELISpot plates were coated with anti–IFNγ (BD Biosciences ELISpot mouse IFNγ Ab
pair) at 1:200 in PBS and incubated overnight at 4˚C. Ten days post-infection, spleens from
each group were harvested. CD4+ or CD8+ T cells were purified from bulk splenocytes using
negative bead isolation (Invitrogen Dynabeads Untouched Mouse CD4+ or CD8+ Isolation
Kit) and incubated with the indicated APCs, with three technical replicates per condition.
After an overnight incubation, the plates were developed (BD Biosciences ELISpot mouse
IFNγ Ab pair and AEC Substrate Kit), and IFNγ spots produced by activated T cells were
counted (ImmunoSpot reader); background signal from mock infection was subtracted from
sample wells.

In vitro infections for ELISpot and flow cytometry
BMDCs or L929 cells were infected in low volume 0.1% BSA/PBS at a multiplicity of infection
(MOI) of 1 for 1.5 hours 37˚C with agitation followed by addition of RPMI 1640 (10% FBS,
antibiotics, L-glutamine, and 2-ME). Cells were then incubated at 37˚C overnight, with an
infection rate of 50–60% observed by flow cytometry. Following infection, cells were washed
and re-suspended for ELISpot or flow staining. For ELISpot, prior to co-culture of infected
cells with T cells, neutralizing antibodies were added to prevent viral spread (anti-B5R and
anti-L1R). The following reagents were obtained through BEI Resources, NIAID, NIH: Monoclonal Anti-Vaccinia Virus (WR) B5R Protein, Residues 20 to 275 (Ectodomain), (similar to
VMC-20), produced in vitro, (NR-50418); Vaccinia Virus (WR) L1R Protein with C-Terminal
Histidine Tag, Recombinant from Baculovirus, (NR-21986).

Focus forming assay
BSC-1 cells were seeded to confluency in 96-well flat bottom dishes overnight. The following
day, infection samples were serially diluted in triplicate, added to wells (having removed
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culture media prior) in 50 uL volume and incubated at 37˚C for 1 hour. Samples were removed
from wells and avicel overlay (1.25% avicel (FMC RC-591 NF) in DMEM) added to wells. The
plates were incubated for 18 hours, prior to fixation with 4% PFA, permeabilization with 0.5%
Triton-X in PBS, and blocking with 5% BSA in TBS-T. Wells were stained with Rb anti-VACV
Ab (Thermo PA1-7258) followed by HRP Gt anti-Rb secondary (CST 7074S). Lastly wells
were incubated with KPL TrueBlue TMB substrate (SeraCare 5510–0049) for 2 hours, washed
with water and air dried. Positively-stained virus-infected foci were counted (ImmunoSpot
Reader).

In vivo viral virulence assay
Female BALB/c mice were inoculated with 3 x 102 pfu ECTVΔC15 or ECTVrevC15 in the
footpad. Mice were weighed on alternate days and monitored for signs of foot pathology as
well as morbidity and mortality daily. Mice that displayed persistent recumbency or lost over
20% of initial body weight were sacrificed in accordance with the Institutional Animal Care
and Use guidelines of the Children’s Hospital of Philadelphia IACUC.

Transfections
Cells were plated in 10cm tissue culture dishes in most cases or in chambered coverglass slides
(Thermofisher) (Fig 8) overnight. At 70–80% confluency cells were transfected with 15 ug or
1ug (Fig 8) of the indicated plasmid using XtremeGENE HP reagent (Sigma Aldrich) in
OPTI-MEM (Thermofisher) in DMEM supplemented with 5% FBS and L-glutamine. At 24
hours post transfection cells were harvested for sorting or prepared for synapse formation
assay.

Flow cytometry
Cells were stained with live/dead Aqua (Thermofisher L34965) prior to staining with antiMHCII (clone M5.114.15.2, Biolegend), anti-CD80 (clone 16-10A1, Biolegend) and antiCD86 (clone GL-1, Biolegend) (Fig 4) on ice for 30 minutes. Cells were washed and fixed in
2% para-formaldehyde (VWR 76221–378) prior to acquisition on an LSRII instrument. For
sorting experiments cells were stained with live/dead Aqua (Thermofisher L34965) prior to
staining with anti-HA (clone 16B12, Biolegend) and sorted using a MoFLo Astrios or FACS
Jazz instrument (Children’s Hospital of Philadelphia Research Institute Flow Cytometry Core
Facility).

In vitro antigen-presentation (MUG) assay
Following transfection and sorting, the indicated cells were co-cultured with epitope-specific
LacZ-inducible T cell hybridomas overnight in 384 well plates (Sigma CLS3571). In indicated
cases, 0.2 mg/mL exogenous peptide was added (>85% purity, Genscript, resuspended in
DMSO). Activation was measured by detection of fluorometric β-galactosidase substrate
methyl-umbelliferyl-β-D-galactopyranoside (MUG; Sigma M1633) as previously described
[21, 24, 86]. With the exception of SF.4, the background signal from mock peptide (DMSO) or
other appropriate negative control denoted in the figure legend was subtracted from the sample signal. Fluorescence was detected on Tecan Infinite M200 Pro Plate Reader.

Superantigen activation ELISpot
The ELISpot as described above was modified in the following manner. Splenic CD4+ T cells
were isolated from C57Bl/6 mice infected intraperitoneally for 10 days with 4 HAU of PR8
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influenza as previously described [24]. At the time of BMDC/T cell co-culture in the ELISpot
plate, 2 ug/mL recombinant SEB (Toxin Technologies Inc.) was added to the appropriate
wells, with three technical replicates per condition. Background signal from mock treated
wells was subtracted from sample wells.

Synapse formation assay
B6-IEd fibroblasts were plated on Lab-Tek II chambered coverglass slides (Thermo Fisher
155409) and allowed to attach overnight. The cells were then transfected with either C15-HA
or Guanyl Cyclase C-HA (GCC-HA) as a control, using XtremeGENE HP reagent (Sigma
Aldrich). After 24 hours, CD4+ T cells from TEα mice or CD8+ T cells from OT-I mice were
allowed to settle on the APCs in L15 media (Gibco) supplemented with 2mg/mL glucose. After
a 30 minute incubation to allow synapse formation, co-cultures were gently washed and fixed
with 3.7% PFA (Electron Microscopy Science) for 15 mins, then blocked and permeabilized in
PBS, 0.01% saponin, 0.05% fish skin gelatin (PSG) for 20 min. Cells were stained with anti-HA
(clone 16B12, Biolegend), anti-CD3 (clone 17A2, Biolegend), fluorescent phalloidin (Life
Technologies Molecular Probes), and Hoechst (Life Technologies Molecular Probes) for 1
hour in PSG. Cells were then washed 3x with PSG, and stained with the appropriately conjugated secondary antibodies (Life Technologies Molecular Probes) for 1 hour in PSG. Cells
were washed 3x with PSG, mounted, and imaged using a 63x PlanApo 1.4 NA objective on an
Axiovert 200M (Zeiss) with a spinning disk confocal system (Ultraview ERS6; PerkinElmer).
For quantification, C15-HA or GCC-HA expressing cells were located, and scored whether for
the presence or absence of a T cell forming a synapse with >50 cells counted per condition.
HA-negative surrounding cells were also scored. To capture representative images, multiple zplanes spanning a total of 10μm were collected with an Orca Flash 4.0 camera (Hamamatsu)
and prepared using ImageJ software; an individual plane is pictured.

Supporting information
S1 Fig. ECTVΔC15 retains virulence in the absence of C15. BALB/c mice were infected with
ECTVΔC15 and monitored daily for foot loss. The death of mice prior to potential foot loss
precluded similar analysis with ECTVrevC15. Representative of two independent experiments.
(TIF)
S2 Fig. C15 restricts endogenous but not indirect MHCII presentation. Three female
C57Bl/6 mice were infected with 3x103 pfu WT ECTV via footpad injection. Ten days later,
mice were sacrificed and spleens were pooled. CD4+ T cells were isolated by negative bead
selection and in the presence of neutralizing antibodies mixed with either BMDCs infected
with ECTVΔC15 or ECTVrevC15 (direct presentation) or infected fibroblasts and uninfected
BMDCs (indirect presentation). CD4+ T cell activation was measured via IFNγ production by
ELISpot. Representative of 3 independent experiments. Significance analyzed by student’s T
test, ��� p<0.001, error bars signify square root of the squared SEMs.
(TIF)
S3 Fig. The C terminus of C15 is extracellular. B6-IEd fibroblasts were transfected with
C15-HA prior to staining for surface expression of HA tag.
(TIF)
S4 Fig. CHO-IEd-epitope stable cell lines activate T cell hybridomas in an epitope specific
manner. Epitope expression in these stable cell lines was verified by co-culturing these cells
with T cell hybridomas specific for each peptide. T cell activation was measured by proxy of β-
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galactosidase conversion of MUG substrate.
(TIF)
S1 Data. Excel spreadsheet containing, in separate sheets, the underlying numerical data
and statistical analysis for Figure panels 1a, 1b, 2b, 2c, 2d, 3a, 3b, 3c, 3d, 4a-f, 6a, 6b, 6c, 7,
8b, 8d, SF1, SF2, SF4.
(XLSX)

Acknowledgments
We thank the labs of Ivan Maillard, Christopher Hunter and Edward Behrens for reagents and
the Flow Cytometry Core at the Children’s Hospital of Philadelphia Research Institute for
technical assistance. We wish to express appreciation to our many colleagues for helpful discussion and communications, in particular Rachel L. Roper.

Author Contributions
Conceptualization: Katherine S. Forsyth, Nathan H. Roy, Brian C. DeHaven, Adam R. Hersperger, Laurence C. Eisenlohr.
Formal analysis: Katherine S. Forsyth, Elise Peauroi.
Funding acquisition: Katherine S. Forsyth, Laurence C. Eisenlohr.
Investigation: Katherine S. Forsyth, Nathan H. Roy, Elise Peauroi, Brian C. DeHaven, Erik D.
Wold.
Methodology: Brian C. DeHaven.
Project administration: Laurence C. Eisenlohr.
Supervision: Janis K. Burkhardt, Laurence C. Eisenlohr.
Validation: Katherine S. Forsyth.
Writing – original draft: Katherine S. Forsyth.
Writing – review & editing: Katherine S. Forsyth, Nathan H. Roy, Elise Peauroi, Brian C.
DeHaven, Erik D. Wold, Adam R. Hersperger, Janis K. Burkhardt, Laurence C. Eisenlohr.

References
1.

Murphy K, Weaver C. Janeway’s Immunobiology. 9 ed. New York: Garland Science 2017.

2.

Forsyth KS, Eisenlohr LC. Giving CD4+ T cells the slip: viral interference with MHC class II-restricted
antigen processing and presentation. Current Opinion in Immunology. 2016; 40:123–9. PubMed Central
PMCID: PMC4894315 https://doi.org/10.1016/j.coi.2016.03.003 PMID: 27115617

3.

Cai Q, Banerjee S, Cervini A, Lu J, Hislop AD, Dzeng R, et al. IRF-4-mediated CIITA transcription is
blocked by KSHV encoded LANA to inhibit MHC II presentation. PLoS Pathogens. 2013; 9(10).
PubMed Central PMCID: PMC3814934

4.

Thakker S, Purushothaman P, Gupta N, Challa S, Cai Q, Verma SC. Kaposi’s Sarcoma-Associated
Herpesvirus Latency-Associated Nuclear Antigen Inhibits Major Histocompatibility Complex Class II
Expression by Disrupting Enhanceosome Assembly through Binding with the Regulatory Factor X Complex. Journal of Virology. 2015; 89(10):5536–56. PubMed Central PMCID: PMC4442538. https://doi.
org/10.1128/JVI.03713-14 PMID: 25740990

5.

Li D, Qian L, Chen C, Shi M, Yu M, Hu M, et al. Down-regulation of MHC class II expression through
inhibition of CIITA transcription by lytic transactivator Zta during Epstein-Barr virus reactivation. Journal
of Immunology. 2009; 182(4):1799–809.

6.

Thorley-Lawson DA. Epstein-Barr virus: exploiting the immune system. Nature Reviews Immunology.
2001; 1(1):75–82. https://doi.org/10.1038/35095584 PMID: 11905817

PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1008685 August 3, 2020

18 / 23

PLOS PATHOGENS

Ectromelia encoded C15 targets MHC class II antigen presentation

7.

Lin JH, Lin JY, Chou YC, Chen MR, Yeh TH, Lin CW, et al. Epstein-Barr virus LMP2A suppresses MHC
class II expression by regulating the B-cell transcription factors E47 and PU.1. Blood. 2015; 125:2228–
39. https://doi.org/10.1182/blood-2014-08-594689 PMID: 25631773

8.

Lee AW, Wang N, Hornell TMC, Harding JJ, Deshpande C, Hertel L, et al. Human cytomegalovirus
decreases constitutive transcription of MHC class II genes in mature Langerhans cells by reducing
CIITA transcript levels. Molecular Immunology. 2011; 48:1160–7. PubMed Central PMCID:
PMC3086682. https://doi.org/10.1016/j.molimm.2011.02.010 PMID: 21458073

9.

Kanazawa S, Okamoto T, Peterlin BM. Tat competes with CIITA for the binding to P-TEFb and blocks
the expression of MHC class II genes in HIV infection. Immunity. 2000; 12(1):61–70. https://doi.org/10.
1016/s1074-7613(00)80159-4 PMID: 10661406

10.

Zuo J, Thomas WA, Haigh TA, Fitzsimmons L, Long HM, Hislop AD, et al. Epstein-Barr virus evades
CD4+ T cell responses in lytic cycle through BZLF1-mediated downregulation of CD74 and the cooperation of vBcl-2. PLoS Pathogens. 2011; 7(12):e1002455. PubMed Central PMCID: PMC3245307.
https://doi.org/10.1371/journal.ppat.1002455 PMID: 22216005

11.

Toussaint H, Gobert F-X, Schindler M, Banning C, Kozik P, Jouve M, et al. Human immunodeficiency
virus type 1 nef expression prevents AP-2-mediated internalization of the major histocompatibility complex class II-associated invariant chain. Journal of Virology. 2008; 82(17):8373–82. PubMed Central
PMCID: PMC2519681. https://doi.org/10.1128/JVI.00670-08 PMID: 18596106

12.

Hegde NR, Tomazin RA, Wisner TW, Dunn C, Boname JM, Lewinsohn DM, et al. Inhibition of HLA-DR
assembly, transport, and loading by human cytomegalovirus glycoprotein US3: a novel mechanism for
evading major histocompatibility complex class II antigen presentation. Journal of Virology. 2002; 76
(21):10929–41. PubMed Central PMCID: PMC136637. https://doi.org/10.1128/jvi.76.21.10929-10941.
2002 PMID: 12368336

13.

Quinn LL, Williams LR, White C, Forrest C, Zuo J, Rowe M. The Missing Link in Epstein-Barr Virus
Immune Evasion: the BDLF3 Gene Induces Ubiquitination and Downregulation of Major Histocompatibility Complex Class I (MHC-I) and MHC-II. Journal of Virology. 2016; 90(1):356–67. PubMed Central
PMCID: PMC4702578. https://doi.org/10.1128/JVI.02183-15 PMID: 26468525

14.

Chianese-Bullock KA, Russell HI, Moller C, Gerhard W, Monaco JJ, Eisenlohr LC. Antigen processing
of two H2-IEd-restricted epitopes is differentially influenced by the structural changes in a viral glycoprotein. Journal of Immunology. 1998; 161(4):1599–607.

15.

Ressing ME, van Leeuwen D, Verreck FAW, Gomez R, Heemskerk B, Toebes M, et al. Interference
with T cell receptor-HLA-DR interactions by Epstein-Barr virus gp42 results in reduced T helper cell recognition. Proceedings of the National Academy of Sciences of the United States of America. 2003; 100
(20):11583–8. PubMed Central PMCID: PMC208801 https://doi.org/10.1073/pnas.2034960100 PMID:
14504389

16.

Mullen MM, Haan KM, Longnecker R, Jardetzky TS. Structure of the Epstein-Barr virus gp42 protein
bound to the MHC class II receptor HLA-DR1. Molecular Cell. 2002; 9(2):375–85. https://doi.org/10.
1016/s1097-2765(02)00465-3 PMID: 11864610

17.

Jacobson S, Sekaly RP, Bellini WJ, Johnson CL, McFarland HF, Long EO. Recognition of intracellular
measles virus antigens by HLA class II restricted measles virus-specific cytotoxic T lymphocytes.
Annals of the New York Academy of Sciences. 1988; 540:352–3. https://doi.org/10.1111/j.1749-6632.
1988.tb27096.x PMID: 2905123

18.

Jacobson S, Sekaly RP, Jacobson CL, McFarland HF, Long EO. HLA class II-restricted presentation of
cytoplasmic measles virus antigens to cytotoxic T cells. Journal of Virology. 1989; 63(4):1756–62.
PubMed Central PMCID: PMC248439. https://doi.org/10.1128/JVI.63.4.1756-1762.1989 PMID:
2784508

19.

Jaraquemada D, Marti M, Long EO. An endogenous processing pathway in vaccinia virus-infected cells
for presentation of cytoplasmic antigens to class II-restricted T cells. Journal of Experimental Medicine.
1990; 172(3):947–54. PubMed Central PMCID: PMC2188531. https://doi.org/10.1084/jem.172.3.947
PMID: 2388037

20.
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